Management of Alveolar Proteinosis by Bronchopulmonary lavage under Extra Corporeal Membrane Oxygenation (ECMO)

Authors

Tahereh Parsa1, Ardeshir TajbakhshArdeshir Tajbakhsh ORCID2, Zargham Hossein AhmadiZargham Hossein Ahmadi ORCID3, Behrooz Farzanegan1, Alireza JahangirifardAlireza Jahangirifard ORCID2,*
1Tracheal Disease Research Center,National Research Institute of Tuberculosis and Lung Diseases (NRITLD), Shahid Beheshti University of Medical Sciences, Tehran, Iran
2Anesthesiology Research Center, Shahid Beheshti University of Medical Sciences, Tehran, Iran
3Transplantation Research Center, National Research Institute of Tuberculosis and Lung Diseases (NRITLD), Shahid Beheshti University of Medical Sciences, Tehran,Iran
*Corresponding Author: Anesthesiology Research Center, Shahid Beheshti University of Medical Sciences, Tehran, Iran Email: [email protected]

Journal of Cellular & Molecular Anesthesia:Vol. 1, issue 1; e150241
Published online:Dec 23, 2015
Article type:Brief Communications
How to Cite:Parsa T, Tajbakhsh A, Hossein Ahmadi Z, Farzanegan B, Jahangirifard A. Management of Alveolar Proteinosis by Bronchopulmonary lavage under Extra Corporeal Membrane Oxygenation (ECMO). J Cell Mol Anesth. 2016;1(1):e150241. doi: https://doi.org/10.22037/jcma.v1i1.10604

Abstract

The gold standard of treating Pulmonary Alveolar Proteinosis (PAP) is bronchopulmonary lavage (BPL). We describe a rare case of BPD for PAP, who underwent extracorporeal membrane oxygenation (ECMO) due to hypoventilation in the setting of one-lung ventilation. First, the clinical course of the patient is presented; furthermore, the biomolecular basis of PAP and new treatment approaches is discussed. ?

References

  • 1.
    References are in the PDF file of the article.

Copyright

© 2016, Author(s). This open-access article is available under the Creative Commons Attribution 4.0 (CC BY 4.0) International License (https://creativecommons.org/licenses/by/4.0/), which allows for unrestricted use, distribution, and reproduction in any medium, provided that the original work is properly cited.

Similar Articles

13
Dec
2012

Whole Lung Lavage of Nine Children with Pulmonary Alveolar Proteinosis: Experience in a Tertiary Lung Center

Badiozaman Radpay,
Tahereh Parsa,
Shideh Dabir,
Mohammadreza Boloursaz,
Ahmadreza Arbab,
Seyyedahmad Tabatabaei

Radpay B, Parsa T, Dabir S, Boloursaz M, Arbab A, et al. Whole Lung Lavage of Nine Children with Pulmonary Alveolar Proteinosis: Experience in a Tertiary Lung Center. Inn J Pediatr. 2013;23(1):. doi:

23
Jul
2013

The Effects of Surfactant on Oxygenation in Term Infants with Respiratory Failure

Serdar Beken,
Canan Turkyılmaz,
Esin Koc,
Ibrahim M. Hirfanoglu,
Nilgun Altuntas

Beken S, Turkyılmaz C, Koc E, M. Hirfanoglu I, Altuntas N. The Effects of Surfactant on Oxygenation in Term Infants with Respiratory Failure. Inn J Pediatr. 2013;23(4):. doi:

15
Nov
2013

A Report of Separation From Mechanical Ventilation in a Patient With Chronic Obstructive Pulmonary Disease (COPD)

Vajihe Biniaz,
Tayyeb Moradyan

Biniaz V, Moradyan T. A Report of Separation From Mechanical Ventilation in a Patient With Chronic Obstructive Pulmonary Disease (COPD). Jundishapur J Chronic Dis Care. 2013;2(4):32248. doi:

29
Apr
2026
Effect of High-frequency Oscillatory Ventilation-Assisted Pulmonary Surfactant Intervention on Children with Neonatal Respiratory Distress Syndrome

Effect of High-frequency Oscillatory Ventilation-Assisted Pulmonary Surfactant Intervention on Children with Neonatal Respiratory Distress Syndrome

Mingxi Chen,
Hao Wang,
Wenjuan Zhang

Chen M, Wang H, Zhang W. Effect of High-frequency Oscillatory Ventilation-Assisted Pulmonary Surfactant Intervention on Children with Neonatal Respiratory Distress Syndrome. Inn J Pediatr. 2026;36(3):e160903. doi: https://doi.org/10.5812/ijpediatr-160903

8
Oct
2019
Cast Bronchitis in a Cystic Fibrosis Child: Experience with Direct Instillation of Dornase Alfa as an Adjunct Treatment Agent

Cast Bronchitis in a Cystic Fibrosis Child: Experience with Direct Instillation of Dornase Alfa as an Adjunct Treatment Agent

Sedigheh Yousefzadegan,
Rohollah Shirzadi,
Safura Navaie,
Alireza Takzare,
Mahdieh Ghaempanah,
Mohammadreza Modaresi

Yousefzadegan S, Shirzadi R, Navaie S, Takzare A, Ghaempanah M, et al. Cast Bronchitis in a Cystic Fibrosis Child: Experience with Direct Instillation of Dornase Alfa as an Adjunct Treatment Agent. Inn J Pediatr. 2019;29(5):e89703. doi: https://doi.org/10.5812/ijp.89703

More by these authors

Tahereh ParsaPubMedScholar
Ardeshir TajbakhshPubMedScholar
Zargham Hossein AhmadiPubMedScholar
Behrooz FarzaneganPubMedScholar
Alireza JahangirifardPubMedScholar
Share
Cited by
Metrics